• No results found

Human embryonic stem cells : advancing biology and cardiogenesis towards functional applications l Braam, S.R.

N/A
N/A
Protected

Academic year: 2021

Share "Human embryonic stem cells : advancing biology and cardiogenesis towards functional applications l Braam, S.R."

Copied!
4
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Human embryonic stem cells : advancing biology and cardiogenesis towards functional applications l

Braam, S.R.

Citation

Braam, S. R. (2010, April 28). Human embryonic stem cells : advancing biology and cardiogenesis towards functional applications l. Retrieved from https://hdl.handle.net/1887/15337

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/15337

Note: To cite this publication please use the final published version (if

applicable).

(2)

8jgg^Xjajbk^iVZ 163

8jgg^Xjajbk^iVZ

Stefan Braam was born on June 15th, 1983 in Dalfsen, the Netherlands. After graduating from secondary school in 2000 (Thomas a Kempis College, Zwolle) he started his bachelor study in Biochemistry at Saxion University, followed by a masters degree in biomedical sciences at Utrecht University. During his bachelor study he performed his first internship under the supervision of Prof. J Galama in the Department of Virology, UMC St Radboud. For his second internship, he moved to the laboratory of Dr. FAE Kruyt, VUMC Amsterdam, to work on adenoviruses for cancer gene therapy.

During his master study (Sept. 2004) he became interested in human embryonic stem cells and he moved to the Hubrecht Institute to work with Prof. Dr Christine L. Mummery and Dr.

Leon G.J. Tertoolen on cardiomyoycte differentiation and electrophysiology. In 2005 he was awarded a WSC award and an Erasmus scholarship to work with Dr C. Denning (Nottingham UK) on human embryonic stem cell technology development. He received his Masters degree cum laude in April 2006.

Subsequently, he started as a PhD candidate supervised by Prof. Dr. C. Mummery at the Hubrecht Institute Utrecht. In 2008 he was awarded a EU Heart Repair travel award to work with Prof. Dr A Elefanty and Prof. Dr. E Stanley at the Monash Immunology and Stem Cell laboratories, Monash University, in Melbourne, Australia. After four months in Australia he continued his research work with Prof. Dr. C Mummery at the Leiden University Medical Centre.

The results of these studies are presented in this thesis.

In 2010 he started working on Pluriomics together with Dr. R. Passier, Dr. Anja van de Stolpe and Prof. Dr. C Mummery. Pluriomics, is a biotech start-up initiative focused on cardiac safety pharmacology and drug discovery and was awarded the first prize in the NGI venture challenge December 2009

(3)

164 A^hid[ejWa^XVi^dch

A^hid[EjWa^XVi^dch

S.R. Braam

t , R Nauw, D Ward-van Oostwaard , C Mummery, R Passier - Inhibition of ROCK improves survival of human embryonic stem cell-derived cardiomyocytes after dissociation - Ann N Y Acad Sci. 2010 Feb;1188:52-7.

Van Hoof D, Dormeyer W,

t Braam SR, Passier R, Monshouwer-Kloots J, Ward-van Oostwaard D, Heck AJ, Krijgsveld J, Mummery CL – Identification of Cell Surface Proteins for Antibody-Based Selection of Human Embryonic Stem Cell-Derived Cardiomyocytes - J Proteome Res. 2010 Mar 5;9(3):1610-8

S.R. Braam

t , L Tertoolen, A van de Stolpe, T Meyer, R Passier, C.L Mummery - Prediction of drug induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes - Stem Cell Research 2010 2010 Mar;4(2):107-16

S.R Braam

t , C. Denning, CL Mummery – Genetic manipulation of human embryonic stem cells in serum and feeder-free media Methods Mol Biol. 2010;584:413-23

S.R Braam

t , R. Passier , C.L Mummery– Cardiomyocytes from pluripotent stem cells in regenerative medicine and drug discovery Trends in Pharmacological sciences 2009 Oct;30(10):536-45. Epub 2009 Sep 15. Cover article

S.R Braam

t (*), D van Hoof (*), J Munoz (*), M.W. Pinkse (*), R. Linding, A.J.R Heck, C.L Mummery, J Krijgsveld – Phosphoryalation dynamics during early differentiation of human embryonic stem cells Cell Stem Cell 2009 Aug 7

S.R Braam

t (*), D van Hoof (*),W Dormeyer, A.J.R Heck, J Krijgsveld, C.L Mummery - Feeder-free human embryonic monolayer cultures express an epithelial plasma membrane protein profile Stem Cells 2008 Nov;26(11):2777-81. Epub 2008 Aug 14.

S.R Braam

t (*), C Denning (*), E Matsa, L.E Young, R Passier, C.L Mummery - Feeder-free culture of human embryonic stem cells in conditioned medium for efficient genetic manipulation, Nature Protocols 2008;3(9):1435-43

S.R Braam

t , L.M Zeinstra, S.H.M Litjens, D Ward-van Oostwaard, S van den Brink, L.W van Laake, F Lebrin, R Passier, A Sonnenberg, C.L Mummery - Recombinant vitronectin is a functionally defined substrate that supports human embryonic stem cell self renewal via αVβ5 integrin, Stem Cells Sep;26(9):2257-65. Epub 2008 Jul 3. Cover article W Dormeyer, D van Hoof,

t S.R Braam, A.J.R Heck, C.L Mummery, J Krijgsveld - Plasma membrane proteomics of human embryonic stem cells and human embryonal carcinoma cells J. Proteome Research 2008 Jul;7(7):2936-51. Epub 2008 May 20.

(4)

A^hid[ejWa^XVi^dch 165

S.R Braam

t , C. Denning, S van den Brink, P Kats, R Hochstenbach, R Passier, C Mummery - Improved genetic manipulation of human embryonic stem cells Nat. Methods 2008 May; 5(5):389-92 Epub 2008 April 6

R. Graichen, X Xu,

t S.R Braam, T. Balakrishnan, S. Norfiza, S. Sieh, S.Y. Yoo, S.C Tham, C.Mummery, A. Colman, R. Zweigerdt, B.P Davidson - Enhanced cardiomyogenesis of human embryonic stem cells by a small molecule inhibitor of p38 MAPK Differentiation 2008 Apr; 76(4):357-70

J.C. Moore, L.W. van Laake,

t S.R Braam, T. Xue, S.Y. Tsang, D. Ward, R. Passier, L.

Tertoolen, R.A Li, C.L. Mummery - Human embryonic stem cells: Genetic Manipulation on the Way to Cardiac Cell Therapies, Reproductive Toxicology 2005 Sep-Oct

M.A.I Abou El Hassan,

t S.R Braam, F.A.E Kruyt - Paclitaxel enhances adenoviral gene expression and assembly in a cell-cycle-independent manner in NCI-H460 cells Cancer Gene Therapy 2006 Dec;13(12):1105-14. Epub 2006 Jul 14

M.A.I. Abou El Hassan,

t S.R Braam, F.A.E Kruyt - A real time PCR assay for the

quantitative determination of adenoviral gene expression in mammalian cells. J Virol.

Methods 2006 Apr;133(1):53-61. Epub 2005 Nov 21

(*) Authors contributed equally

Scientific Awards

Recipient Bolk prize – Dutch society for Anatomy, January 2010 t

Winner NGI venture challenge - Pluriomics , December 2009 t

Heartrepair FP6 travel grant to Monash University, Melbourne Australia, April 2008 t

Recipient Wijck-Stam-Caspers award, January 2007 t

Erasmus grant for internship University of Nottingham, September 2006 t

Referenties

GERELATEERDE DOCUMENTEN

To develop a generic method for ectopic gene expression in hESC, we investigated whether twelve independently derived cell lines (HES-2, Envy, HUES1,5,7,15, HESC-NL1,2,3,4 and

The major difference from procedures described by others previously is the use of Matrigel in combination with feeder cell conditioned medium to culture the cells in a true

Like cells located at the periphery of hESC colonies cultured on feeder cells (as described here for lines HUES-7 and HES-2, and previously for VUB01 16 , feeder-free hESC also

Three independently derived cell lines (HUES1, HES2 and HESC-NL3) were cultured long term on recombinant vitronectin in mTeSR1 medium and all maintained their characteristic

Although mouse ESC (mESC) and hESC have a similar core transcriptional regulatory network, involving OCT4 3 , SOX2 4,5 , and NANOG 6 , they differ in their growth requirements..

FACS based purification of early NKX2-5 positive cells revealed a multipotent progenitor population capable of directed differentiation to the cardiac, endothelial and vascular

Efficient, reproducible differentiation of hESC to ventricular cardiomyocytes, preferably phenotypically similar to adult human cardiomyocytes, is of critical importance for

In this review we will discuss the opportunities for cardiomyocytes derived from human pluripotent stem cells with respect to cell therapy, safety pharmacology and drug development